Clearside Biomedical, Inc. (CLSD)

Clearside Biomedical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	28.92	48.26	30.44	17.55	22.96
Cash & Cash Equivalents	28.92	48.26	30.44	17.55	22.96
Cash Growth	-40.07%	58.56%	73.45%	-23.56%	-44.34%
Receivables	0.17	0	10	0	0
Other Current Assets	1.03	1.14	1.7	0.57	2.26
Total Current Assets	30.12	49.4	42.14	18.12	25.22
Property, Plant & Equipment	3.87	1.87	0.61	0.94	1.2
Other Long-Term Assets	0.03	0.03	0.16	0.26	0.36
Total Long-Term Assets	3.9	1.9	0.77	1.2	1.56
Total Assets	34.02	51.3	42.9	19.32	26.78
Accounts Payable	2.21	1.05	0.94	2	1.28
Deferred Revenue	0.08	0.21	0	5	5
Current Debt	0.36	0.35	0.39	1.36	1.69
Other Current Liabilities	4.17	4.18	3.31	1.58	2.93
Total Current Liabilities	6.81	5.78	4.64	9.94	10.9
Long-Term Debt	42.64	34.91	0.29	0.62	4.72
Other Long-Term Liabilities	0.48	0	0	0	0
Total Long-Term Liabilities	43.12	34.91	0.29	0.62	4.72
Total Liabilities	49.93	40.7	4.93	10.56	15.62
Total Debt	43	35.26	0.68	1.98	6.41
Debt Growth	21.95%	5124.00%	-65.91%	-69.11%	-35.75%
Retained Earnings	-320.92	-288.44	-255.49	-255.87	-237.66
Shareholders' Equity	-15.91	10.61	37.98	8.76	11.16
Net Cash / Debt	-14.08	13	29.76	15.57	16.55
Net Cash / Debt Growth	-	-56.33%	91.18%	-5.92%	-47.07%
Net Cash Per Share	-0.23	0.22	0.50	0.33	0.43
Working Capital	23.31	43.62	37.5	8.18	14.32
Book Value Per Share	-0.26	0.18	0.65	0.19	0.29

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).